{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:32:01Z","timestamp":1786545121206,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1038\/ajg.2011.220","type":"journal-article","created":{"date-parts":[[2011,8,16]],"date-time":"2011-08-16T08:05:49Z","timestamp":1313481949000},"page":"1953-1960","source":"Crossref","is-referenced-by-count":31,"title":["Withdrawing PPI Therapy After Healing Esophagitis Does Not Worsen Symptoms or Cause Persistent Hypergastrinemia: Analysis of Dexlansoprazole MR Clinical Trial Data"],"prefix":"10.14309","volume":"106","author":[{"given":"David C","family":"Metz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy L","family":"Pilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia M","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-17-20210210","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1046\/j.1365-2036.1997.00257.x","article-title":"Review article: the pharmacological inhibition of gastric acid secretiontolerance and rebound.","volume":"11","author":"Sandvik","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"R4-17-20210210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3748\/wjg.v13.i4.493","article-title":"Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion.","volume":"13","author":"Cui","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R5-17-20210210","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/00365520903477348","article-title":"Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint.","volume":"45","author":"Waldum","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"R6-17-20210210","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2036.2006.03171.x","article-title":"Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors.","volume":"25","author":"Hunfeld","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-17-20210210","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/ajg.2010.81","article-title":"Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial.","volume":"105","author":"Niklasson","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R10-17-20210210","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1517\/14656560903198978","article-title":"Dexlansoprazole MR.","volume":"10","author":"Aslam","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"R11-17-20210210","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1365-2036.2009.03984.x","article-title":"Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.","volume":"29","author":"Metz","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-17-20210210","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1185\/03007990802693883","article-title":"Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.","volume":"25","author":"Vakily","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R13-17-20210210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1358\/dot.2010.46.2.1437714","article-title":"Dexlansoprazole for the treatment of esophagitis and GERD.","volume":"46","author":"Davies","year":"2010","journal-title":"Drugs Today (Barc)"},{"key":"R14-17-20210210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0016-5085(99)70118-6","article-title":"Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status.","volume":"116","author":"Gillen","year":"1999","journal-title":"Gastroenterology"},{"key":"R15-17-20210210","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2036.2009.03933.x","article-title":"Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulationresults from two randomized controlled studies.","volume":"29","author":"Sharma","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-17-20210210","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2036.2009.03954.x","article-title":"Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.","volume":"29","author":"Metz","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-17-20210210","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2036.2009.04119.x","article-title":"Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90mg in healed erosive oesophagitis - maintenance of healing and symptom relief.","volume":"30","author":"Howden","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-17-20210210","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1046\/j.1365-2036.2000.00768.x","article-title":"Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.","volume":"14","author":"Laine","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-17-20210210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2036.1987.tb00623.x","article-title":"Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole.","volume":"1","author":"Lanzon-Miller","year":"1987","journal-title":"Aliment Pharmacol Ther"},{"key":"R20-17-20210210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2036.1999.00466.x","article-title":"Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.","volume":"13","author":"Sanduleanu","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-17-20210210","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004836-200109000-00007","article-title":"Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?","volume":"33","author":"Farup","year":"2001","journal-title":"J Clin Gastroenterol"},{"issue":"Suppl 1","key":"R22-17-20210210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2036.2005.02611.x","article-title":"Review article: the long-term use of proton-pump inhibitors.","volume":"22","author":"Raghunath","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-17-20210210","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2036.2006.02982.x","article-title":"Persistence and adherence to proton pump inhibitors in daily clinical practice.","volume":"24","author":"Van Soest","year":"2006","journal-title":"Aliment Pharmacol Ther"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2011220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2011220","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2011220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201111000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:36:42Z","timestamp":1786541802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201111000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2011.220","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}